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Summary
The prevalence of vitamin D deficiency in critical illness is known to be high and associated with adverse clinical outcomes. 
Patients receiving extracorporeal membrane oxygenation (ECMO) may be at increased risk of vitamin D deficiency due to high 
severity of acute illness. Challenges with drug dosing in ECMO patients are recognised due to increased volume of distribution 
and drug absorption to circuit components. To describe the prevalence of vitamin D deficiency in ECMO patients and the 
effect of intramuscular dosing of cholecalciferol on levels of vitamin D metabolites, and to compare these data with intensive 
care unit (ICU) patients not receiving ECMO, two prospective studies were performed sequentially: an observational study of 
100 consecutive ICU patients and an interventional study assessing effects of intramuscular cholecalciferol in 50 ICU patients. 
The subgroup of patients who required ECMO support in each of these studies was analysed and compared to patients who 
did not receive ECMO. Twenty-four ECMO patients, 12 from the observational study and 12 from the interventional study 
(who received intramuscular cholecalciferol) were studied—21/24 (88%) ECMO patients were vitamin D deficient at baseline 
compared to 65/126 (52%) of non-ECMO patients (P=0.006). Of the 12 ECMO patients who received cholecalciferol, six 
patients (50%) achieved correction of deficiency compared to 36/38 (95%) non-ECMO patients (P=0.001). The prevalence of 
vitamin D deficiency is higher in ECMO patients compared to other critically ill adults. Correction of deficiency with single dose 
cholecalciferol is not reliable; higher or repeated doses should be considered to correct deficiency. 
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pharmacokinetics
Traditionally, vitamin D has been recognised for its key 
role in musculoskeletal health and calcium metabolism. In 
addition to facilitating calcium absorption from the intestine 
and suppressing parathyroid hormone (PTH) levels, it 
performs important functions in the bone. 
The activated form of vitamin D is recognised by its 
receptor in osteoblasts causing an increase in the expression 
of receptor activator of nuclear factor kappa B ligand 
(RANKL). Its receptor, RANK on the pre-osteoclast, binds 
RANKL, which induces the pre-osteoclast to become a 
mature osteoclast. The mature osteoclast removes calcium 
and phosphorus from bone to maintain blood calcium 
and phosphorus levels. Adequate calcium and phosphorus 
levels promote the mineralisation of the skeleton. Vitamin 
D deficiency is known to cause bone disease—rickets in 
children and osteomalacia or osteoporosis in adults1.
Over the past decade, the pleiotropic role of vitamin D 
beyond its biological function in maintaining musculoskeletal 
health has been the subject of intense interest and research 
focus. 
This has been driven by the finding that most body 
tissues have receptors for the active form of vitamin D, 1,25 
dihydroxy-vitamin D [1,25 (OH)2D], known as vitamin D 
receptors. Additionally, most of these tissues also contain the 
enzyme CYP27B1, which is responsible for the conversion of 
the major circulating form of vitamin D, 25-hydroxy-vitamin D 
[25(OH)D] to its active metabolite 1,25 (OH)2D. Regulation of 
this conversion at tissue level differs from the conventional 
activation that occurs in the kidney in that it is more 
substrate dependent and hence more susceptible to vitamin 
D deficiency2.
The non-skeletal, or otherwise known as pleiotropic, actions 
of vitamin D are mediated by the control of gene expression 
in a number of organs such as the brain, prostate, colon 
and immune cells, which may be of particular relevance in 
critical illness. These non-skeletal actions result in regulation 
of cellular proliferation, differentiation, apoptosis and 
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angiogenesis3. In fact the mechanism of action of vitamin D 
in these contexts is analogous to the way in which steroid 
hormones act. As a result of this contemporary knowledge, 
vitamin D is considered more a hormone than a vitamin.
An emerging body of evidence indicates that vitamin D 
supplementation may be associated with reduced risk of 
death in diseases including multiple sclerosis, autoimmune 
disorders, infections, cardio-metabolic disorders and cancer4.
Several studies have shown that the critically ill population 
is a vulnerable cohort with a high prevalence of vitamin D 
deficiency5-10 ranging between 38% and 100%, which is 50% 
higher than that reported in hospitalised general medical 
patients11. Hypovitaminosis D during critical illness has 
been reported to be associated with adverse outcomes that 
include increased risk of death, longer duration of mechanical 
ventilation and intensive care unit (ICU) stay, increased rates 
of ventilator-associated pneumonia, blood culture positivity 
and organ dysfunction, particularly acute kidney injury6,8,12-15.
Patients supported with extracorporeal membrane 
oxygenation (ECMO) fall within the extreme spectrum of 
illness severity in the ICU, requiring extracorporeal life 
support for severe respiratory and/or cardiac failure that is 
refractory to conventional organ support therapies. These 
patients spend extended periods of time in the ICU and 
in hospital, and frequently have underlying comorbidities 
prior to the index acute ICU admission. This makes them 
vulnerable to vitamin D deficiency when they present to 
the ICU, or developing this during their prolonged critical 
illness. Besides, ECMO therapy may change pharmacokinetics 
by increasing the volume of distribution (Vd), decreasing 
drug elimination, and sequestering drugs within the ECMO 
circuit. Perturbations in achieving therapeutic drug dosing of 
sedatives, analgesics and antibiotics have been reported16,17.
However, there are limited data on the impact of 
commencement of ECMO on the Vitamin D-PTH axis. 
As part of a program of vitamin D assessment and 
supplementation in critical illness, we undertook two serial 
studies of vitamin D status—an observational study of the 
vitamin D-PTH-calcium axis followed by a study assessing the 
effects of two different doses of intramuscular cholecalciferol 
in common clinical use. Within these two studies, patients 
who required ECMO support appeared to have distinct 
characteristics and response to supplementation. This report 
describes the characteristics of these ECMO patients with 
respect to their vitamin D status, the disposition of serum 
vitamin D in patients receiving ECMO, and the effects on 
vitamin D levels of supplementing vitamin D in comparison to 
critically ill patients who did not receive ECMO.
We hypothesised that:
1. There would be a greater prevalence of vitamin D defi-
ciency in patients on ECMO as compared to the non-
ECMO critically ill patient.
2. The response to a supplemental dose of vitamin D would 
be attenuated in the ECMO patients as compared to non-
ECMO patients.
Methods
This study describes the group of patients receiving ECMO 
support within two previously conducted consecutive studies 
on vitamin D in critical illness and compares them to patients 
who did not receive ECMO support8,18.
The first was a multicentre, inception observational cohort 
study in three tertiary centres in Sydney, New South Wales, 
of vitamin D status and metabolites in 100 consecutive ICU 
patients who were expected to stay in ICU for more than two 
days. Patients on renal replacement therapy were excluded. 
The second study was a prospective, randomised open label 
interventional study of supplementation of a single dose of 
vitamin D (cholecalciferol), with either 150,000 IU or 300,000 
IU intramuscularly, in patients who were expected to stay 
in the ICU for more than two days. Patients were excluded 
if they were pregnant, hypercalcaemic, had chronic kidney 
disease, had a coagulopathy (contraindicating intramuscular 
injection) or had a condition associated with pathological 1–
alpha-hydroxylase activity.
Within these cohorts, patients who received ECMO were 
analysed separately. These patients were managed using 
a Quadrox D hollow-fibre oxygenator (Maquet® Rastatt, 
Germany) and a Jostra pump head (Maquet® Rastatt, 
Germany) for ECMO support either in a veno-venous (VV) 
configuration for respiratory failure, veno-arterial (VA) 
configuration for primary cardiac support or veno-pulmonary 
artery (VPA) configuration for right ventricular support 
following implantation of a left ventricular assist device 
(LVAD). Indications for commencement, management, 
anticoagulation, weaning and separation from ECMO were 
based on established protocols at a quaternary referral 
ECMO, VAD and cardiopulmonary transplant centre. Patients 
received enteral nutrition and on rare occasions, parenteral 
nutrition when enteral nutrition was contraindicated or could 
not be established successfully as per protocol. None of 
the patients received additional vitamin D supplementation 
other than that present within the nutritional solutions. 
(approximately 200–400 IU/day). Apart from ECMO support, 
patients received standard ICU care in terms of ventilatory 
management, vasoactive medications and antimicrobial 
therapies.
Data collection
In both studies, baseline demographic, diagnostic and 
severity of illness (Simplified Acute Physiology Score II and 
Acute Physiology and Chronic Health Evaluation II) data were 
collected on admission to the ICU. 
In addition to routine blood tests performed during 
standard ICU care, in the observational study, serum 
concentrations of 25(OH)D, 1,25(OH)2D, intact PTH (two-
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site immunoassay for intact PTH), and ionised calcium were 
measured at baseline and on day 3 and either at day 7 or at 
ICU discharge if this was prior to day 3 or 7. 
In the interventional study, serum 25(OH)D and 1,25(OH)2D 
and PTH concentrations were measured at baseline, day 1, 
day 3, day 7, and day 14 (or until discharge from the ICU, 
whichever was earlier) following administration of the 
cholecalciferol dose. 
Assays
25(OH)D in nmol/l was measured using liquid 
chromatography mass spectrometry (Waters, Milford, MA, 
USA) in a single reference laboratory (average coefficient of 
variation [CV] of the three quality control [QC] levels 6.2%). 
1,25(OH)2D in pmol/l was measured by radioimmunoassay 
(DiasSorin Cat No 65100E, Saluggia, Italy) (average CV of 
the three QC levels 22.4%). PTH analysis was performed 
by immunoassay with Beckman DxI 800 immunoanalyser 
(Beckman Coulter, Brea, CA, USA) (average CV of the three 
QC levels 6.6%). Ionised calcium was measured using an ion-
sensitive electrode (Radiometer ABL 720 blood gas analyser, 
CV 1.3%).
Vitamin D deficiency was defined as a 25(OH)D level less 
than 50 nmol/l (note 1 ng/ml=2.5 nmol/l). This was based 
on the 2010 Institute of Medicine report where a group 
of experts estimated that a vitamin D level of 50 nmol/l or 
higher was adequate for good bone health, and considered a 
level less than 50 nmol/l as vitamin D deficiency19.
Statistical analysis
Continuous variables were not normally distributed and 
hence described as median (interquartile range, IQR). 
Differences between groups were tested by using Mann–
Whitney U test for continuous variables or Fisher’s exact 
test for proportions. Changes in 25(OH)D concentrations 
during follow-up in the 12 patients who did not receive 
cholecalciferol were compared with a mixed linear model. 
A P-value of less than or equal to 0.05 was considered 
statistically significant. 
Ethics approval
Human Research Ethics Committee (HREC) approval was 
obtained in the local jurisdiction separately for both studies 
and informed consent was obtained either from the patient 
or more frequently from the next of kin (Reference numbers 
HREC/09/SVH/165 and HREC/12/SVH/322 respectively).
Results
Twelve patients in the observational and 12 patients in 
the interventional study received ECMO, resulting in a total 
of 24 ECMO patients, 12 of whom were supplemented with 
cholecalciferol. 
Patients in the ECMO group were younger, had a longer 
duration of ICU and hospital stay and a higher mortality 
suggesting an overall increased illness severity, although 
illness severity scores did not reflect this (Table 1).
Patients who required ECMO support received either VA 
ECMO for cardiac and respiratory support, VV ECMO for 
respiratory support alone, or VPA ECMO for right ventricular 
support following LVAD implantation (Table 2).
Table 1
Patient characteristics
All
(n=150)
ECMO 
patients
(n=24)
Non-ECMO 
patients 
(n=126)
P-value
Age, years, median 
(IQR)
53 (40–66) 46 (33–55) 55 (41–68) 0.007*
Male gender, n (%) 101 (67%) 15 (60%) 86 (68%) 0.44
APACHE II score, 
median (IQR)
20 (15–25) 22 (17–30) 20 (15–25) 0.16
ICU LOS, days,  
median (IQR)
10 (5–17) 19 (14–29) 8 (4–14) <0.00001*
Hospital LOS, days, 
median (IQR)
24 (14–40) 32 (23–57) 24 (13–34) 0.02*
Hospital mortality, 
n (%)
17 (11%) 8 (33%) 9 (6.5%) 0.0001*
* P <0.05, difference between ECMO patients and non-ECMO patients. 
ECMO, extracorporeal membrane oxygenation; APACHE, Acute Physiology 
and Chronic Health Evaluation; ICU, intensive care unit; LOS, length of stay; 
IQR, interquartile range.
Table 2
a) Diagnostic categories for all patients at intensive care admission (n=150)
Diagnostic category n
Infection/sepsis 52
Cardiac surgical and medical 35
Trauma 26
Neurological 7
Metabolic 7
Transplant – heart or lung 20
Miscellaneous 3
b) Indications for extracorporeal membrane oxygenation support (n=24)
Diagnostic group n ECMO 
configuration
Cardiogenic shock 10 VA
Sepsis 2 VA
Respiratory failure 4 VV
LVAD perioperative support 5 VPA
Primary graft dysfunction, heart or lung 
transplant
3 VA=2, VV=1
VA, veno-arterial; VV, veno-venous; VPA, veno-pulmonary artery; LVAD, left 
ventricular assist device; ECMO, extracorporeal membrane oxygenation.
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Hormonal profiles
At baseline, 21/24 (88%) ECMO patients were vitamin D 
deficient. In the interventional dosing study, 5/6 (83.3%) of 
patients in each of the two dosing groups were deficient at 
baseline. Comparatively, the prevalence of deficiency in the 
non-ECMO patients was significantly lower at 65/126 (52%) 
(P=0.006). The median (IQR) baseline 25(OH)D level in the 
ECMO group was 35 (27–42) nmol/l compared with 40 (27–
58) nmol/l in the non-ECMO group (P=0.02). 
Baseline values of other parameters such as 1,25(OH)2D, 
PTH and ionised calcium were not significantly different 
(Table 3).
In the 12 ECMO patients who did not receive a 
cholecalciferol dose, 25(OH)D levels did not change 
significantly from baseline to day 3 (P=0.37) or day 7 (P=0.18) 
(Table 4). 
Of the 12 ECMO patients who received cholecalciferol 
supplementation, six patients (50%) achieved correction of 
deficiency (>50 nmol/l). In the non-ECMO patients 36 of 38 
(95%) patients achieved correction of their vitamin D levels 
over the study duration (P=0.001) (Figure 1). Observed 
changes were similar with both doses of cholecalciferol 
(150,000 IU and 300,000 IU) and therefore individual dose 
groups are not reported separately.
The incidence of correction (defined as the achievement 
of a serum 25(OH)D level >50 nmol/l) in the ECMO group, 
as in the entire patient cohort, was no different between 
those receiving the 150,000 IU or 300,000 IU dose of 
cholecalciferol. 
There were no occurrences of hypervitaminosis D, 
hypercalcaemia or renal calculi in the ECMO patients 
who received supplementation with cholecalciferol. In 
the non-ECMO patient group who received intramuscular 
cholecalciferol, one patient from the 150,000 IU group was 
observed to have asymptomatic hypercalcaemia (ionised 
calcium >1.3 mmol/l) on day 7. No other complications were 
seen in either group.
Discussion
This study demonstrates that severely ill patients 
receiving ECMO for organ support are almost universally 
deficient in 25(OH)D, the storage form of the vitamin 
used to assess vitamin D sufficiency. The concentrations 
of the active metabolite 1,25(OH)2D were observed to be 
in the normal range in these patients. Administration of 
a single intramuscular dose of cholecalciferol resulted in 
normalisation of 25(OH)D concentrations in only half the 
study population. This is despite the fact that they were 
relatively younger than their counterparts who did not 
receive ECMO. 
Vitamin D levels remained relatively static through the 
first week of ICU stay, suggesting that conventional nutrition 
provided to ICU patients does not provide adequate 
supplementation. 
Despite this high prevalence of low 25(OH)D levels (storage 
form), the levels of the active metabolite 1,25(OH)2D were 
maintained. This is because in the context of vitamin D 
deficiency, the consequent rise in PTH facilitates an increase 
in the renal conversion to 1,25 (OH)2D as a compensatory 
mechanism. The levels of 1,25(OH)2D are 1000-fold less than 
25(OH)D and circulating levels are generally maintained even 
in the setting of severe vitamin D deficiency20. Furthermore, 
the levels of 1,25(OH)2D assayed are circulating levels which 
do not necessarily reflect the tissue level responsible for the 
paracrine pleiotropic functions described previously.
Table 3
Vitamin D and metabolites at baseline
All ECMO 
patients 
(n=24) 
Non-ECMO 
patients 
(n=126)
P-value
25(OH)D, nmol/l, median (IQR) 35 (27–42) 40 (27–58) 0.02*
1,25(OH)2D, pmol/l, median (IQR) 72 (46–128) 71 (47–123) 0.89
PTH, pmol/l, median (IQR) 5 (2.7–10.5) 6 (4–11) 0.9
Ionised calcium, mmol/l, 
median (IQR)
1.07 
(1.02–1.1)
1.08  
(1.02–1.14)
0.4
ECMO, extracorporeal membrane oxygenation; PTH parathyroid hormone; 
IQR, interquartile range.
Table 4
Serum 25(OH)D levels over time in extracorporeal membrane oxygenation 
patients who did not receive supplementation
Baseline
Median (IQR)
Day 3
Median (IQR)
Day 7
Median (IQR)
32 (27–36) 27 (21–38) 31 (25–38)
Using linear mixed model, P-value for difference between at day 3 is 0.37 
and at day 7 is 0.18. IQR, interquartile range.
Figure 1: Serum 25(OH)D levels in the 12 ECMO patients and 38 non-
ECMO patients who received cholecalciferol supplementation. ECMO, 
extracorporeal membrane oxygenation.
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The kinetics of vitamin D in critically ill patients, even 
without ECMO, are altered compared to a healthy population. 
Czarnik et al described unstable levels of vitamin D, which 
mirrored the severity of illness, i.e. critical instability at 
the beginning, steady state and then stabilisation. They 
postulated that the instability of the vitamin D serum 
concentration could also relate to a decrease in circulating 
albumin and vitamin D binding protein (VDBP), which 
typically occurs after fluid resuscitation in the ICU, decreased 
synthesis of VDBP, renal wasting of vitamin D, interstitial 
extravasation caused by increased vascular permeability 
following an inflammatory reaction, lack of exposure to 
sunlight, poor nutrition, decreased renal production of 
1,25(OH)2D, and increased tissue conversion of 25(OH)D to 
1,25(OH)2D
21.
A study that undertook hourly assays of vitamin 
D in a cohort of ICU patients demonstrated marked 
variability during a 24-hour period22. Another study using 
cardiopulmonary bypass as a model for haemodilution 
(such as might be seen in the resuscitative phase of critical 
illness) demonstrated that haemodilution significantly 
lowered serum 25(OH)D levels, which took up to 24 hours 
to resolve23. Therefore interpreting a single measurement in 
critically ill patients to assess deficiency risk or to consider 
supplementation requires caution.
ECMO support is likely to impose further perturbations on 
the kinetics of vitamin D.
In the group of patients who received single high dose 
cholecalciferol supplementation, correction of vitamin D 
levels was more difficult to achieve compared to those 
not receiving ECMO. This could be due to the altered 
pharmacokinetics associated with the extracorporeal circuit 
as well as other factors such as illness severity, intense 
inflammation etc.
There is a paucity of studies on pharmacokinetics in adult 
ECMO patients, although there have been a few studies in 
paediatric and neonatal populations. An ex vivo study of 
different neonatal and paediatric ECMO circuits described 
the kinetics of selected sedatives and antibiotics24. The 
investigators demonstrated that significant absorption 
of drugs occurs in the ECMO circuit, which correlated 
with increased lipophilicity of the drug. Centrifugal pump 
circuits with hollow-fibre membrane oxygenators show less 
absorption for all drugs, but the difference for lipophilic drugs 
is most pronounced. 
A review by Shekar et al25 described the basis of the 
pharmacokinetic alterations observed in ECMO patients 
to be due to haemodilution from priming or transfusion, 
sequestration or inactivation within the circuit, inflammation/
sepsis and/or organ failure and drug factors such as 
lipophilicity. All these factors may result in alteration in the 
Vd, bioavailability, maximum concentration and clearance 
of drugs depending on their individual physicochemical 
properties. 
Shekar et al were able to demonstrate in an ex vivo 
study using a standard adult ECMO circuit, that commonly 
used antibiotics, sedatives and analgesics were variably 
sequestered in the circuit with significant loss at 24 hours of 
fentanyl, midazolam and meropenem, but not vancomycin16.
In another ex vivo study in ECMO patients, looking at 
the disposition of micro- and macronutrients, significant 
alterations in concentrations were described. This was 
particularly the case for isoleucine, an essential amino acid, 
and the vitamins A and E, but not D. The authors suggested 
that the lipophilicity of vitamins A and E might explain their 
loss, but were not able to explain the relatively stable levels 
of vitamin D26.
Hak et al investigated PTH and calcitriol (1,25(OH)2D) levels 
in neonatal patients receiving ECMO27. Hypercalcaemia was 
found to be a common complication in ECMO patients. With 
hypercalcaemia, plasma concentrations of PTH are expected 
to reduce with an increase in calcitonin levels. The authors 
observed aberrant calcitriol-endocrine regulation of calcium 
in these patients and postulated a number of mechanisms 
for the altered endocrine status. Calcitriol levels were not 
investigated in these patients. This and other vitamin D 
studies suggest that the paediatric ICU population might 
mirror adult critical illness including the presence of ECMO 
support28,29. 
Our study is an in vivo study in a critically ill cohort with 
severe organ failure and extracorporeal support, compared 
to ex vivo studies described by other authors. It is the first 
study to report vitamin D status and supplementation in adult 
ECMO patients with systematic prospective data collection, 
multiple measurements and precise time intervals from 
baseline, and describe detailed profiling of the vitamin D 
metabolites, PTH and calcium. 
However, this study is limited with its small sample size and 
the heterogeneity in illness severity and indication for ECMO. 
Due to this small and heterogeneous group of patients, 
appropriate propensity matching could not be performed. 
As a result, a small group of patients (ECMO cohort) was 
compared to a larger group of critically ill patients, which 
does not take into consideration power calculations but 
provides biochemical data on a patient group with extreme 
pathophysiological derangements. Although vitamin D 
supplementation was undertaken with a single dose, we 
have previously shown that single-dose intramuscular 
cholecalciferol is a safe and effective supplementation 
strategy30.
Our study showed the widespread prevalence of vitamin D 
deficiency in this critically ill subgroup of patients receiving 
ECMO. While this most likely relates to their high overall 
illness severity, it suggests that there may be other similar 
groups such as those receiving other forms of extracorporeal 
support who are similarly at greater risk of deficiency within 
a general, heterogeneous ICU population. 
The difficulty in achieving therapeutic levels with 
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supplementation may apply to other lipophilic drugs 
administered to ECMO patients and therefore regular 
therapeutic drug monitoring is required where possible, 
especially for life-saving drugs. Although this study can only 
speculate on the mechanism of deficiency and difficulty 
with supplementation in this small subgroup of patients, it 
is hypothesis-generating and may provide a basis for further 
exploration into this complex area.
With the growing application of ECMO, for any future trials 
of vitamin D supplementation in critically ill patients, this 
group of patients may require to be a predefined subgroup, 
or excluded from such trials, to obtain meaningful results.
Conclusions
Vitamin D deficiency is even more common in ECMO 
patients than in a standard ICU population. Supplementation 
cannot be reliably achieved with conventional single-dose 
therapy; higher or repeated doses need to be considered 
to achieve target supplementation. Given the pleiotropic 
benefits of vitamin D, achieving adequate supplementation 
may be an important consideration in this group of patients 
with high illness severity.
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